Results of using the neuroprotective drug Cellex in non-traumatic intracranial hemorrhage-Reference-Cited by-同舟云学术

Results of using the neuroprotective drug Cellex in non-traumatic intracranial hemorrhage

Published:2022-03-14 Issue:2 Volume: Page:135-145
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Mongush Kh. D.¹^ORCID,Kyrgys A. V.²^ORCID,Sedip A. A.²^ORCID,Shyyrap A. E.²^ORCID,Ondar A. B.²^ORCID,Zhestikova M. G.³^ORCID

Affiliation:

1. Republican Hospital No. 1; Scientific Research Institute of Medical-Social Problems and Management of the Republic of Tuva

2. Republican Hospital No. 1

3. Novokuznetsk State Institute of Postgraduate Medicine – Branch of the Russian Medical Academy of Continuous Professional Education

Abstract

Introduction.In the Russian Federation, neuroprotective agents are widely used in the treatment of patients with ischemic stroke. There are accumulated data on the efficacy and safety of the neuroprotective agent Cellex® in ischemic stroke. The use of this drug in hemorrhagic stroke has been studied to a lesser extent.Aim. To study the efficacy and safety of Cellex® in non-traumatic intracerebral hemorrhage.Materials and methods. The study included 60 patients with hypertensive intracerebral hemorrhage aged 30 to 80 years. Thirty patients (the main group) received Cellex 0.1 mg (1 ml) once a day for 10 days in addition to basic therapy; the remaining 30 patients (control group) received only basic therapy. Over the course of 30 days, the patients were evaluated for various parameters on the Glasgow Coma Scale, stroke severity on the NIHSS scale, patient disability on the Modified Rankin Scale, Barthel Index and Rivermead Mobility Index, speech disorders on the Speech Questionnaire, cognitive function on the Montreal Cognitive Scale (MoCA), and other parameters.Results and discussion. The survival rate was higher in the treatment group than in the control group (p = 0.0237). Speech function improved from 17.0 (14.0–22.0) to 25.0 (21.0–27.0) scores (p = 0.0073) in the Cellex group, no significant improvement in speech function was noted in the control group. There was a trend toward a more significant reduction in stroke severity according to the NIHSS scale and inpatient disability according to the Rankin, Barthel, and Rivermead scales in the Cellex group compared with the control group. Cognitive function on MoCA score improved in Cellex® group from 14.0 (12.0; 22.5) to 20.0 (14.5; 25.0). No adverse events were observed in the group of patients taking Cellex.Conclusion. The efficacy and safety of Cellex® in patients with hypertensive intracerebral hemorrhage has been proven.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference30 articles.

1. Gusev E.I., Skvortsova V.I. Brain ischaemia. Moscow: Meditsina; 2001. 328 p. (In Russ.) Available at: https://vk.com/doc248088279_437512083?hash=614624b1423b9557c4&dl=90f723149d47f299c2.

2. Skvortsova V.I., Stakhovskaya L.V. A set of measures to improve medical care for patients with vascular diseases in the Russian Federation 2008–2013. In: Proceedings of the Russian scientific-practical conference “Impaired cerebral circulation: diagnosis, prevention, treatment.” Pyatigorsk; 2010. (In Russ.).

3. Vakhnina N.V. Treatment of ischemic stroke. RMJ. 2008;(12):1641. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Lechenie_ishemicheskogo_insulyta_1/.

4. Stakhovskaya L.V., Rumyantseva S.A., Silina E.V., Belskaya G.N., Chefranova Zh.Yu., Novikova L.B., Popov D.V. Treatment of ischemic carotid stroke from the standpoint of evidence-based medicine (results of a multicenter, double-blind, randomized, placebo-controlled clinical trial). Lechebnoe Delo. 2013;(2):46–52. (In Russ.) Available at: http://lech-delo.by/wp-content/uploads/arxiv/ld/lech_delo_2_(30)_2013.pdf.

5. Skvortsova V.I., Stakhovskaya L.V., Ayriyan N.Yu. Epidemiology of stroke in the Russian Federation. Systemic Hypertension. 2005;2(1):10–12. (In Russ.) https://doi.org/10.26442/SG28725.